ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 99 • 2014 ACR/ARHP Annual Meeting

    Impact of Comorbidities on Health Resource Utilization in Patients with Spa

    Mariano Andrés1, Francisca Sivera2, Sabina Pérez-Vicente3, Loreto Carmona4 and Paloma Vela1,5, 1Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, 2Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, 3Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, 4Instituto de Salud Musculoesquelética, Madrid, Spain, 5Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain

    Background/Purpose: Similar to other rheumatic disorders, patients with spondyloarthritis (SpA) show an increased prevalence of comorbidities compared to the general population [1]. Comorbidities influence management,…
  • Abstract Number: 102 • 2014 ACR/ARHP Annual Meeting

    Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom

    Frances Humby1, Stephen Kelly1, Angela V. Bedenbaugh2, Nawab Qizilbash3,4, Jochen Dunkel5, Belén SanJose3, Ignacio Mendez3, Jennifer Timoshanko6 and Jeyanesh Tambiah2, 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 2UCB Pharma, Smyrna, GA, 3OXON Epidemiology, London, United Kingdom, 4Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, 5UCB Pharma, Monheim, Germany, 6UCB Pharma, Slough, United Kingdom

    Background/Purpose Several anti-TNFs are currently approved in Europe for RA treatment including certolizumab pegol (CZP), adalimumab (ADA), etanercept (ETN), golimumab and infliximab. UK NICE guidance…
  • Abstract Number: 107 • 2014 ACR/ARHP Annual Meeting

    Use of Internet in Adolescents and Young Adults with JIA

    Philomine A. van Pelt1, Constance H.C. Drossaert2, Radboud JEM Dolhain3, A.a. Kruize4, Jaap Huisman5 and Nico Wulffraat6, 1Rheumatology, Erasmus MC, Rotterdam, Netherlands, 2Psychology, Health and Technology, University of Twente, Enschede, Netherlands, 3Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 4Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Pediatric Psychology, Wilhelmina's Children Hospital UMC Utrecht, Utrecht, Netherlands, 6Paediatric Immunology and Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose Internet-use is increasing since it is an efficient way to find information. Information obtained via Health Related Internet (HRI) sites, or online peer support…
  • Abstract Number: 80 • 2014 ACR/ARHP Annual Meeting

    Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry

    Michael Kruse Meyer1, Marlene Andersen2, Grethe N. Andersen1 and Allan Stensballe3, 1Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, 2Department of Rheumatology, Aalborg University, Hjørring, Denmark, 3Health Science and Technology, Aalborg University, Aalborg, Denmark

    Background/Purpose: In this study we are analyzing leukocyte subtype responses from patients with rheumatoid arthritis (RA) to IL6 inhibition. A large contribution to RA immunopathogenesis…
  • Abstract Number: 79 • 2014 ACR/ARHP Annual Meeting

    PECAM-1 GENE Polymorphisms and Soluble PECAM-1 LEVEL in Rheumatoid Arthritis and Systemic LUPUS Erythematosus Patients Is There a Link with Clinical Atherosclerotic Events?

    Omer Nuri Pamuk1, Hilmi Tozkir2, Mehmet Sevki Uyanik3, Hakan Gurkan4, Julide Duymaz4, Salim Donmez5, Metin Yazar2 and Gulsum Pamuk3, 1Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, 2Genetics, Trakya University Medical Faculty, EDIRNE, Turkey, 3Hematology, Trakya University Medical Faculty, Edirne, Turkey, 4Trakya University Medical Faculty, EDIRNE, Turkey, 5Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey

    Background/Purpose: Platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) which plays a role in the transmigration of leucocytes into tissues is a member of the immunoglobulin (Ig) superfamily.…
  • Abstract Number: 78 • 2014 ACR/ARHP Annual Meeting

    a HPLC-SRM-MS Based Method for the Detection and Quantification of Methotrexate Used at Doses in Clinical Practice for Patients with Rheumatological Disease in Urine

    James Bluett1, Isabel Riba-Garcia2, Richard Unwin2, Suzanne Verstappen3 and Anne Barton4,5, 1Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, 2Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 5Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom

    Background/Purpose Methotrexate (MTX) is a recommended first-line therapy in 2013 EULAR guidelines for active rheumatoid arthritis (RA). Despite this, up to 54% do not adequately…
  • Abstract Number: 77 • 2014 ACR/ARHP Annual Meeting

    Epigenome Profiling Reveals Robust Hypomethylation of Interferon Signature Genes in Lupus Neutrophils

    Patrick Coit1, Sri Yalavarthi1, Wenpu Zhao2, Mariana J. Kaplan2 and Amr H. Sawalha1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

    Background/Purpose: Lupus neutrophils play an important role in tissue damage (including glomerulonephritis and lupus skin involvement), as well as endothelial damage in lupus patients. Several…
  • Abstract Number: 96 • 2014 ACR/ARHP Annual Meeting

    Comparison of Cardiovascular Risk Factor Management in Patients with RA and Matched Non-RA Patients

    H Cawston1, E Alemao2, F Bourhis1, T Le3, M Al4, M Rutten-van Molken4, Katherine Liao5 and DH Solomon6, 1OptumInsight, Nanterre, France, 2Bristol-Myers Squibb, Princeton, NJ, 3Bristol-Myers Squibb, Hopewell, NJ, 4Erasmus University, Rotterdam, Netherlands, 5Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose : The relative risk of acute myocardial infarction in RA patients (pts) has been shown to range from 1.5 to 2.0, with a 1.4–2.7-fold…
  • Abstract Number: 95 • 2014 ACR/ARHP Annual Meeting

    Comparison of Patient Characteristics, Healthcare Costs, and Biologic Persistence Between Patients with Rheumatoid Arthritis Initiating First- or Second-Line Subcutaneous Abatacept, Adalimumab, or Etanercept

    S Johnston1, F Lobo2, D McMorrow1, R Fowler1, D Smith1 and A Nadkarni2, 1Truven Health Analytics, Bethesda, MD, 2Bristol-Myers Squibb, Plainsboro, NJ

    Background/Purpose: There are currently very limited comparative published data on the characteristics, healthcare costs, and biologic persistence among patients with RA who have been treated…
  • Abstract Number: 94 • 2014 ACR/ARHP Annual Meeting

    Possible Effects of Medicare-Only Insurance Coverage on the Use of Biologics in Patients with RA

    Marcia Genta, Dallas Arthritis Center, Dallas, TX

    Background/Purpose: Biologics, a relatively new widely used class of medication that can substantially improve the course of RA, are expensive and their use is not…
  • Abstract Number: 93 • 2014 ACR/ARHP Annual Meeting

    Protein Profiling of Secretome Human Cartilage to Identify Potential EARLY Specific Biomarkers in Osteoarthritis

    Lucia Lourido, Valentina Calamia, Patricia Fernandez-Puente, Jesus Mateos, Francisco J. Blanco Garcia, Beatriz Rocha, Carolina Fernández-Costa, Carlos Fernandez-Lopez, Natividad Oreiro and Cristina Ruiz-Romero, Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain

    Background/Purpose: Osteoarthritis (OA) is characterized by the progressive loss of cartilage structural extracellular matrix (ECM) components. The release of these proteins from the tissue can…
  • Abstract Number: 92 • 2014 ACR/ARHP Annual Meeting

    Long Noncoding RNA Nron Regulates the Activity of NFAT5 through Ubiquitin-Independent Proteasome Pathway in Rheumatoid Arthritis

    Kunihiko Umekita1,2, Michelle Trenkmann1, Christoph Kolling3, Akihiko Okayama4, Renate Gay1, Steffen Gay1 and Mojca Frank Bertoncelj5, 1Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, 2Department of Rheumatology, Infectious diseases and Laboratory medicine, University of Miyazaki, Miyazaki, Japan, 3Schulthess Clinic, Zurich, Switzerland, 4Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, 5Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: Long noncoding RNAs (lncRNAs) are increasingly recognized as master regulators of gene expression. The lncRNA NRON, noncoding repressor of nuclear factor of activated T…
  • Abstract Number: 91 • 2014 ACR/ARHP Annual Meeting

    Quantitative Proteomics Using Dimethyl Isotope Labeling for Comparison of Fresh Frozen Versus Formalin-Fixed, Paraffin-Embedded Tissue for Lupus Nephritis

    Abhimanyu Amarnani1, Joseph Capri2, Puneet Souda3, David Elashoff4, Ivan Lopez5, Julian Whitelegge3 and Ram Singh1, 1Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, 2Pasarow Mass Spectrometry Laboratory, University of California, Los Angeles, Los Angeles, CA, 3The Pasarow Mass Spectrometry Laboratory, University of California, Los Angeles, Los Angeles, CA, 4Medicine/Statistics Core, University of California, Los Angeles, Los Angeles, CA, 5Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA

    Background/Purpose Lupus nephritis (LN) progresses from mild focal inflammation, to diffuse proliferative nephritis, to fibrosis and end-stage renal disease. Though the understanding of LN has…
  • Abstract Number: 89 • 2014 ACR/ARHP Annual Meeting

    Global miRNA Expression Profiling in Peripheral Blood and Synovial Fluid Mononuclear Cells of Patients with Enthesitis Related Arthritis

    Sushma Singh, Ramnath Misra and Amita Aggarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: Enthesitis related arthritis (ERA) is the most common category of JIA in India. MicroRNA dysregulation has been associated with arthritis and autoimmune diseases. In…
  • Abstract Number: 88 • 2014 ACR/ARHP Annual Meeting

    Microbiomes of Inflammatory and Non-Inflammatory Thoracic Aortic Aneurysms

    Pauline Funchain*1,2,3, Gary S. Hoffman*4, Lars Svensson5, Eric Roselli5, Gosta Pettersson6, Douglas Johnston6, Edward Soltesz6, Ritu Chakravarti7, Alison Clifford8 and Charis Eng2, 1Genomic Medicine Institute, Lerner Research Institute, Cleveland, OH, 2Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, 3Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, 4Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 5Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, 6Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, 7Lerner Research Institure, Cleveland Clinic, Cleveland, OH, 8Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Aortitis may occur in the context of multifocal large and medium-sized vessel diseases such as giant cell arteritis (GCA) or Takayasu arteritis (TAK) and…
  • « Previous Page
  • 1
  • …
  • 2043
  • 2044
  • 2045
  • 2046
  • 2047
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology